Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Gene Can Help Predict Chemotherapy Outcomes For Breast Cancer Patients, Study Shows
Testing for genetic mutations can help identify breast cancer patients who do not benefit from a certain type of chemotherapy, according to a study published Tuesday in the journal Clinical Cancer Research, Reuters reports. The study included 588 breast cancer patients in the U.S. and Norway. Some of the subjects received chemotherapy, while some did not. The study found that chemotherapy patients with a certain mutation of the SOD2 gene had a higher risk of dying than those with no SOD2 mutation. It also found that those with a second type of SOD2 variation were the most likely to die. The researchers also divided the groups based on the type of chemotherapy drugs they received. The SOD2 mutations were the best indicator of who would fare better from treatment with the drug cyclophosphamide, they found. Women in this group who had a certain variant of the SOD2 mutation were the most likely to die, according to the study.The researchers suggested that testing patients for the SOD2 gene mutations before beginning treatment with cyclophosphamide could be helpful. Stefan Ambs of the National Cancer Institute, who took part in the study, said, "In the future, such tests may be used to guide the treatment of patients with the SOD2 variation, ensuring that they receive a therapy that is more effective than cyclophosphamide-based therapies" (Reuters, 6/9).

FDA Approves NovoLog(R) Labeling Update Increasing The Time Patients Can Use And Store NovoLog(R) In Their Pumps From Two Days To Six Days
Diabetes patients taking NovoLog® (insulin aspart [rDNA origin] injection) can now use the insulin in their pump for up to six days following the U.S. Food and Drug Administration (FDA) approval of a labeling change, diabetes care company Novo Nordisk announced today.[i] The previous label allowed for NovoLog® to be stored in the pump reservoir for two days. This makes NovoLog® the first and only rapid-acting insulin with this extended in-use time.
News of the day
Prevalence Of Ureaplasma Urealyticum And Mycoplasma Hominis In Women With Chronic Urinary Symptoms
UroToday.com - Ureaplasma urealyticum and Mycoplasma Hominis are members of a unique group of microorganisms commonly identified in the genital tract of women. With the onset of sexual intercourse the prevalence of Mycoplasma increases dramatically an isolation is strongly dependent on the number of sexual partners. Convincing evidence of an infection caused by genital Mycoplasma is not easy, because they usually are not isolated in pure culture, making the evaluation even more difficult.
Diagnostics

BJOG Release: New Study On The Cause Of Early Preterm Birth

An exploratory study to be published in BJOG: An International Journal of Obstetrics and Gynaecology, has shown that women going into early preterm labour (before 34 weeks gestation) have low-levels of progesterone in their saliva as early as 24 weeks, and that moreover, these levels fail to rise during pregnancy in the normal way. This offers the possibility of developing a simple, non-invasive test to identify women at increased risk of delivering early. Progesterone is a hormone which helps regulate the menstrual cycle; but perhaps most importantly, it is the primary hormone of pregnancy. It is produced in large amounts from the placenta and acts to stop the womb from contracting. Researchers at University College London and King"s College London, collected specimens of saliva from 92 women taking part in an existing randomised control trial (the PREMET study) of preventive treatment for preterm birth. Women recruited to the study all had an increased risk of having a preterm birth (they were selected based on having at least one risk factor such as a history of previous preterm birth, late miscarriage etc). Saliva samples were taken from these women every week from 24 weeks gestation until 34 weeks or delivery (whichever was the sooner), and analysed. Women were divided into three groups: delivery before 34 weeks, delivery between 34 - 37 weeks and delivery at term (after 37 weeks). The results show that the concentration of progesterone in the saliva of women delivering after spontaneous labour before 34 weeks was significantly lower than those giving birth at term (after 37 weeks) at all gestational ages from 24 weeks onwards. The authors note that progesterone is known for its anti-inflammatory properties, and suggest that low levels of the hormone in the maternal body could contribute to bacterial infection, a recognised cause of early preterm labour. Based on their findings, researchers believe saliva progesterone could be a useful predictor of early preterm labour and delivery. Lead author Professor Lucilla Poston, from the Maternal and Fetal Research Unit at King"s College London said, "This very interesting study, funded by Tommy"s, backs up previous research which hinted at the importance of low saliva progesterone as a marker for labour onset. "We are now planning a much larger study to validate these preliminary findings. Saliva is easy to collect, there is no need for a needle or a blood sample and it would be wonderful if in the future we only had to ask a pregnant woman to produce a small sample of saliva to know whether or not she was at risk of very early premature birth." Jane Brewin, Tommy"s Chief Executive, added: "We are delighted with the results of this initial study. Backed by further research, we hope these findings will also have an impact on the development of preventative measures for preterm births." Professor Philip Steer, BJOG editor-in-chief, said "Despite advances in medicine, we are still a long way from understanding the causes of preterm birth in the human. "This promising study, though small, suggests that salivary progesterone measurement could provide a useful early identification of women with an increased chance of an early premature birth. Further prospective research is needed on a larger cohort. Finding a reliable marker of impending preterm birth would allow us to try and develop targeted preventative measures." Notes Children born prematurely (References Lachelin G, McGarrigle H, Seed P, Briley A, Shennan A, Poston L. Low saliva progesterone concentrations are associated with spontaneous early preterm labour (before 34 weeks of gestation) in women at increased risk of preterm delivery. BJOG 2009; DOI: 10.1111/j.1471-0528.2009.02293.x. Royal College of Obstetricians and Gynaecologists


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009